A Study to Evaluate the Safety and Efficacy of RQC for AMD
NCT ID: NCT05062486
Last Updated: 2025-07-30
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
55 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-10-04
Study Completion Date
2024-11-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration (AMD).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients
NCT04590196
Age Related Macular Degeneration
COMPLETED
EARLY_PHASE1
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
NCT01048476
Age-related Macular Degeneration
UNKNOWN
PHASE1/PHASE2
Eye and Carotenoid Augmentation Research and Evaluation (EyeCARE)
NCT06848101
Vision
Eye Health
ACTIVE_NOT_RECRUITING
NA
Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration
NCT01528605
Age-related Macular Degeneration
COMPLETED
NA
Resveratrol for Exudative Age-Related Macular Degeneration
NCT02625376
AMD
Age-related Macular Degeneration
Choroidal Neovascularisation
TERMINATED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The objective of the study is to institute an open-label, randomized, double arm, phase 2 study to evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) versus curcumin alone (C) in AMD. The primary outcomes are change in drusen volume, geographic atrophy growth rate, and progression to moderate vision loss. Progression to advanced AMD will serve as a secondary outcome measure. Participants are classified by pre-AMD severity at baseline and randomized into either the C (n=50) or RQC (n=150) arm. Curcumin is taken orally at a dose of 1000 mg twice per day. RQC is taken orally at a dose of 100 mg resveratrol, 120 mg quercetin, and 1000 mg curcumin twice per day. The study will be conducted over 2 years with follow-up visits at least every 6 months.
Safety is evaluated using adverse event reporting, vital sign/physical examinations, and blood testing. Efficacy is evaluated using a series of OCT-based retinal photography and image processing techniques to measure drusen volume, GA area, and the presence of advanced disease (GA or wet AMD). Progression to moderate vision loss is defined as a loss of 15 letters on the Early Treatment for Diabetic Retinopathy Study (ETDRS) charts. The status of 15 single nucleotide polymorphisms reported to be associated with AMD are analyzed and incorporated as covariates into multivariate models of primary and secondary outcomes.
Safety is evaluated using adverse event reporting, vital sign/physical examinations, and blood testing. Efficacy is evaluated using a series of OCT-based retinal photography and image processing techniques to measure drusen volume, GA area, and the presence of advanced disease (GA or wet AMD). Progression to moderate vision loss is defined as a loss of 15 letters on the Early Treatment for Diabetic Retinopathy Study (ETDRS) charts. The status of 15 single nucleotide polymorphisms reported to be associated with AMD are analyzed and incorporated as covariates into multivariate models of primary and secondary outcomes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Age-related Macular Degeneration
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Resveratrol, Quercetin, Curcumin (RQC)
Resveratrol (100mg BID), Quercetin (120mg BID), Curcumin (1000mg BID); 24 months
Group Type
EXPERIMENTAL
Resveratrol, Quercetin, Curcumin (RQC)
Intervention Type
DRUG
100 mg resveratrol, 120 mg quercetin, 1000 mg curcumin BID
Curcumin
Curcumin (1000mg BID); 24 months
Group Type
ACTIVE_COMPARATOR
Curcumin
Intervention Type
DRUG
1000 mg curcumin BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Resveratrol, Quercetin, Curcumin (RQC)
100 mg resveratrol, 120 mg quercetin, 1000 mg curcumin BID
Intervention Type
DRUG
Curcumin
1000 mg curcumin BID
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male or female of any race or ethnicity.
2. Aged 50-90 years at time of study entry.
3. Ability to speak, read, and understand English.
4. Ability to take oral medication and be willing to adhere to the study regimen.
5. Capable of providing informed consent/provision of signed and dated informed consent.
6. Stated willingness to comply with all procedures and availability for the duration of the study.
7. Diagnosis of dry AMD (AREDS categories Early, drusen 63-124 µm in width; Intermediate, drusen ≥125 µm in width; or Advanced, macular geographic atrophy) as documented by OCT and/or color retinal photography.
2. Aged 50-90 years at time of study entry.
3. Ability to speak, read, and understand English.
4. Ability to take oral medication and be willing to adhere to the study regimen.
5. Capable of providing informed consent/provision of signed and dated informed consent.
6. Stated willingness to comply with all procedures and availability for the duration of the study.
7. Diagnosis of dry AMD (AREDS categories Early, drusen 63-124 µm in width; Intermediate, drusen ≥125 µm in width; or Advanced, macular geographic atrophy) as documented by OCT and/or color retinal photography.
Exclusion Criteria
1. Participation in another clinical study with an investigational product during the last 90 days.
2. The presence of wet AMD.
3. The presence of ocular disease or condition that may confound evaluation of the retina or could require medical or surgical intervention.
4. Previous retinal or other ocular surgical procedures (other than cataract extraction) that may have complicated assessment of the progression of AMD.
5. A serious or complex systemic medical disease or condition with a poor five-year survival prognosis or that would make adherence or follow-up difficult or unlikely.
6. Diagnosis of Alzheimer's disease or dementia, diagnosis of a serious gastrointestinal or stomach condition, or positive for HIV, hepatitis B surface antigen, or hepatitis C antibodies.
7. History of inherited bleeding disorder.
8. Use of any anticoagulant medication within 5 days before the first dose of investigative product is scheduled or required for subsequent medical treatment in the course of the study.
9. Clinically significant abnormal physical examination/vital signs or laboratory and coagulation blood tests as deemed appropriate by the investigator.
10. History of or a reason to believe participant has a history of drug or alcohol abuse within the past 5 years.
11. History of known allergy to any component of the investigational product.
12. Preplanned surgery or procedures that would interfere with the conduct of the study.
13. Currently incarcerated prisoners.
14. Currently pregnant or lactating.
2. The presence of wet AMD.
3. The presence of ocular disease or condition that may confound evaluation of the retina or could require medical or surgical intervention.
4. Previous retinal or other ocular surgical procedures (other than cataract extraction) that may have complicated assessment of the progression of AMD.
5. A serious or complex systemic medical disease or condition with a poor five-year survival prognosis or that would make adherence or follow-up difficult or unlikely.
6. Diagnosis of Alzheimer's disease or dementia, diagnosis of a serious gastrointestinal or stomach condition, or positive for HIV, hepatitis B surface antigen, or hepatitis C antibodies.
7. History of inherited bleeding disorder.
8. Use of any anticoagulant medication within 5 days before the first dose of investigative product is scheduled or required for subsequent medical treatment in the course of the study.
9. Clinically significant abnormal physical examination/vital signs or laboratory and coagulation blood tests as deemed appropriate by the investigator.
10. History of or a reason to believe participant has a history of drug or alcohol abuse within the past 5 years.
11. History of known allergy to any component of the investigational product.
12. Preplanned surgery or procedures that would interfere with the conduct of the study.
13. Currently incarcerated prisoners.
14. Currently pregnant or lactating.
Minimum Eligible Age
50 Years
Maximum Eligible Age
90 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Paul A Knepper, MD PhD
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Paul A Knepper, MD PhD
Sponsor-Investigator
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul A Knepper, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Zaparackas Knepper, Ltd
Zibute Zaparackas, MD
Role: PRINCIPAL_INVESTIGATOR
Zaparackas Knepper, Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zaparackas M.D. & Knepper M.D. Ph.D., Ltd
Chicago, Illinois, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Almeida L, Vaz-da-Silva M, Falcao A, Soares E, Costa R, Loureiro AI, Fernandes-Lopes C, Rocha JF, Nunes T, Wright L, Soares-da-Silva P. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009 May;53 Suppl 1:S7-15. doi: 10.1002/mnfr.200800177.
Reference Type
BACKGROUND
Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron. 2012 Jul 12;75(1):26-39. doi: 10.1016/j.neuron.2012.06.018.
Reference Type
BACKGROUND
Barratt-Due A, Pischke SE, Nilsson PH, Espevik T, Mollnes TE. Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targets. J Leukoc Biol. 2017 Jan;101(1):193-204. doi: 10.1189/jlb.3VMR0316-132R. Epub 2016 Aug 31.
Reference Type
BACKGROUND
Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1246-52. doi: 10.1158/1055-9965.EPI-07-0022.
Reference Type
BACKGROUND
Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010 Nov 15;70(22):9003-11. doi: 10.1158/0008-5472.CAN-10-2364. Epub 2010 Oct 8.
Reference Type
BACKGROUND
Byun EB, Yang MS, Choi HG, Sung NY, Song DS, Sin SJ, Byun EH. Quercetin negatively regulates TLR4 signaling induced by lipopolysaccharide through Tollip expression. Biochem Biophys Res Commun. 2013 Feb 22;431(4):698-705. doi: 10.1016/j.bbrc.2013.01.056. Epub 2013 Jan 24.
Reference Type
BACKGROUND
Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003 Feb;9(1):161-8. doi: 10.1089/107555303321223035.
Reference Type
BACKGROUND
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001 Jul-Aug;21(4B):2895-900.
Reference Type
BACKGROUND
AREDS2 Research Group; Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A, McBee W, Sperduto R, Ferris FL. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology. 2012 Nov;119(11):2282-9. doi: 10.1016/j.ophtha.2012.05.027. Epub 2012 Jul 26.
Reference Type
BACKGROUND
Chew EY, Lindblad AS, Clemons T; Age-Related Eye Disease Study Research Group. Summary results and recommendations from the age-related eye disease study. Arch Ophthalmol. 2009 Dec;127(12):1678-9. doi: 10.1001/archophthalmol.2009.312. No abstract available.
Reference Type
BACKGROUND
Cottart CH, Nivet-Antoine V, Beaudeux JL. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res. 2014 Jan;58(1):7-21. doi: 10.1002/mnfr.201200589. Epub 2013 Jun 6.
Reference Type
BACKGROUND
Davis MD, Gangnon RE, Lee LY, Hubbard LD, Klein BE, Klein R, Ferris FL, Bressler SB, Milton RC; Age-Related Eye Disease Study Group. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol. 2005 Nov;123(11):1484-98. doi: 10.1001/archopht.123.11.1484.
Reference Type
BACKGROUND
Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008 Jul 15;14(14):4491-9. doi: 10.1158/1078-0432.CCR-08-0024.
Reference Type
BACKGROUND
Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank J, Rimbach G, Mueller MJ. Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr. 2008 Sep;138(9):1615-21. doi: 10.1093/jn/138.9.1615.
Reference Type
BACKGROUND
Ferris FL 3rd, Bailey I. Standardizing the measurement of visual acuity for clinical research studies: Guidelines from the Eye Care Technology Forum. Ophthalmology. 1996 Jan;103(1):181-2. doi: 10.1016/s0161-6420(96)30742-2. No abstract available.
Reference Type
BACKGROUND
Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, Sadda SR; Beckman Initiative for Macular Research Classification Committee. Clinical classification of age-related macular degeneration. Ophthalmology. 2013 Apr;120(4):844-51. doi: 10.1016/j.ophtha.2012.10.036. Epub 2013 Jan 16.
Reference Type
BACKGROUND
Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J, Kerr DJ. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 1996 Apr;2(4):659-68.
Reference Type
BACKGROUND
Feuer WJ, Yehoshua Z, Gregori G, Penha FM, Chew EY, Ferris FL, Clemons TE, Lindblad AS, Rosenfeld PJ. Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: a reanalysis of age-related eye disease study report no. 26. JAMA Ophthalmol. 2013 Jan;131(1):110-1. doi: 10.1001/jamaophthalmol.2013.572. No abstract available.
Reference Type
BACKGROUND
Gradisar H, Keber MM, Pristovsek P, Jerala R. MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol. 2007 Oct;82(4):968-74. doi: 10.1189/jlb.1206727. Epub 2007 Jul 3.
Reference Type
BACKGROUND
Grunwald JE, Pistilli M, Ying GS, Maguire MG, Daniel E, Martin DF; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015 Apr;122(4):809-16. doi: 10.1016/j.ophtha.2014.11.007. Epub 2014 Dec 24.
Reference Type
BACKGROUND
Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013 Jan;15(1):195-218. doi: 10.1208/s12248-012-9432-8. Epub 2012 Nov 10.
Reference Type
BACKGROUND
Handa JT, Bowes Rickman C, Dick AD, Gorin MB, Miller JW, Toth CA, Ueffing M, Zarbin M, Farrer LA. A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration. Nat Commun. 2019 Jul 26;10(1):3347. doi: 10.1038/s41467-019-11262-1.
Reference Type
BACKGROUND
Hewlings SJ, Kalman DS. Curcumin: A Review of Its Effects on Human Health. Foods. 2017 Oct 22;6(10):92. doi: 10.3390/foods6100092.
Reference Type
BACKGROUND
Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, Sartor RB. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999 Sep 15;163(6):3474-83.
Reference Type
BACKGROUND
Keenan TD, Agron E, Domalpally A, Clemons TE, van Asten F, Wong WT, Danis RG, Sadda S, Rosenfeld PJ, Klein ML, Ratnapriya R, Swaroop A, Ferris FL 3rd, Chew EY; AREDS2 Research Group. Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16. Ophthalmology. 2018 Dec;125(12):1913-1928. doi: 10.1016/j.ophtha.2018.05.028. Epub 2018 Jul 27.
Reference Type
BACKGROUND
la Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, Singhal N, Cameron DW. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet. 2010 Jul;49(7):449-54. doi: 10.2165/11531820-000000000-00000.
Reference Type
BACKGROUND
Merle NS, Paule R, Leon J, Daugan M, Robe-Rybkine T, Poillerat V, Torset C, Fremeaux-Bacchi V, Dimitrov JD, Roumenina LT. P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6280-6285. doi: 10.1073/pnas.1814797116. Epub 2019 Mar 8.
Reference Type
BACKGROUND
Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond). 2016 Dec 22;3:34. doi: 10.1186/s40662-016-0063-5. eCollection 2016.
Reference Type
BACKGROUND
Seddon JM, Silver RE, Kwong M, Rosner B. Risk Prediction for Progression of Macular Degeneration: 10 Common and Rare Genetic Variants, Demographic, Environmental, and Macular Covariates. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2192-202. doi: 10.1167/iovs.14-15841.
Reference Type
BACKGROUND
Suresh K. An overview of randomization techniques: An unbiased assessment of outcome in clinical research. J Hum Reprod Sci. 2011 Jan;4(1):8-11. doi: 10.4103/0974-1208.82352.
Reference Type
BACKGROUND
Vadhan-Raj S, Weber DM, Wang M, Giralt SA, Thomas SK, Alexanian R, Zhou X, Patel P, Bueso-Ramos CE, Newman RA, Aggarwal BB. Curcumin downregulates NF-kB and related genes in patients with multiple myeloma: results of a phase I/II study. Blood. 2007;110(11):1177.
Reference Type
BACKGROUND
Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014 Feb;2(2):e106-16. doi: 10.1016/S2214-109X(13)70145-1. Epub 2014 Jan 3.
Reference Type
BACKGROUND
Youn HS, Lee JY, Fitzgerald KA, Young HA, Akira S, Hwang DH. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J Immunol. 2005 Sep 1;175(5):3339-46. doi: 10.4049/jimmunol.175.5.3339.
Reference Type
BACKGROUND
Youn HS, Saitoh SI, Miyake K, Hwang DH. Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem Pharmacol. 2006 Jun 28;72(1):62-9. doi: 10.1016/j.bcp.2006.03.022. Epub 2006 Apr 1.
Reference Type
BACKGROUND
Koronyo Y, Biggs D, Barron E, Boyer DS, Pearlman JA, Au WJ, Kile SJ, Blanco A, Fuchs DT, Ashfaq A, Frautschy S, Cole GM, Miller CA, Hinton DR, Verdooner SR, Black KL, Koronyo-Hamaoui M. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease. JCI Insight. 2017 Aug 17;2(16):e93621. doi: 10.1172/jci.insight.93621. eCollection 2017 Aug 17.
Reference Type
BACKGROUND
Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, Schwartz M, Farkas DL. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage. 2011 Jan;54 Suppl 1:S204-17. doi: 10.1016/j.neuroimage.2010.06.020. Epub 2010 Jun 13.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZK-01-2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy
NCT02984813
TERMINATED
PHASE1
Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression
NCT05465252
RECRUITING
NA
Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation
NCT02264938
COMPLETED
NA
The Influence of Lutein Supplements on Age-related Macular Degeneration
NCT01042860
COMPLETED
NA
Curcumin and Retinal Study
NCT05774704
RECRUITING
PHASE1/PHASE2
Carotenoid Supplementation and Retinal Health in Healthy Adults
NCT07314411
RECRUITING
NA
Oxidative Stress in Patients With Age-Related Macular Degeneration
NCT00465400
COMPLETED
Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60
NCT00121589
COMPLETED
PHASE1
The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil
NCT01680510
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene
NCT01145196
RECRUITING
Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD)
NCT01527435
COMPLETED
Possible Effects of Supplement Therapy With Oral Phenolics on Cluster of Differentiation 163 (CD-163) Biomarker of Patients With Age-related Macular Degeneration
NCT05005884
UNKNOWN
PHASE1
The Role of the Gut Metagenome on the Development of Age Related Macular Degeneration (AMD)
NCT02438111
UNKNOWN
Effect of Micronutrient Supplementation on the Intestinal Microbiota in Patients With Age-related Macular Degeneration - The Gut-Retina-axis Study
NCT06391411
COMPLETED
NA
Antioxidant Systems and Age-Related Macular Degeneration
NCT00668213
COMPLETED
Effect of Saffron Supplementation on Macular Cone-mediated Function in Age-related Macular Degeneration
NCT00951288
UNKNOWN
PHASE1/PHASE2
Morpho-functional Changes After Oral Supplementation of Antioxidants and Anti-inflammatory Treatment in Age-Related Macular Degeneration.
NCT03919019
COMPLETED
NA
Regional Kale as Source of Lutein and Zeaxanthin to Improve Vision of AMD-patients
NCT02136303
UNKNOWN
NA
Effects of Antioxidants on Human Macular Pigments
NCT00718653
COMPLETED
NA
The Zeaxanthin and Visual Function Study
NCT00564902
COMPLETED
NA
"Night Vision and Carotenoids"
NCT04741763
COMPLETED
NA
Lutein for Age-Related Macular Degeneration
NCT00006202
COMPLETED
PHASE2
Effect of Carotenoids Supplementation on Visual Function in Chinese Subjects
NCT06098677
NOT_YET_RECRUITING
NA
Age-related Macular Degeneration (AMD) and Cardiovascular Disease
NCT04087356
UNKNOWN
Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
NCT00800995
COMPLETED
PHASE3